Literature DB >> 27222502

Dynamic Changes in Renal Function Are Associated With Major Cardiovascular Events in Patients With Type 2 Diabetes.

Stéphanie Ragot1, Pierre-Jean Saulnier2, Gilberto Velho3, Elise Gand4, Astrid de Hauteclocque5, Yousri Slaoui6, Louis Potier3, Philippe Sosner7, Jean-Michel Halimi8, Philippe Zaoui9, Vincent Rigalleau10, Frederic Fumeron3, Ronan Roussel3, Michel Marre3, Samy Hadjadj11.   

Abstract

OBJECTIVE: The pattern of renal function decline prior to cardiovascular (CV) events in type 2 diabetes is not well known. Our aim was to describe the association between renal function trajectories and the occurrence of a CV event. RESEARCH DESIGN AND METHODS: We considered patients with type 2 diabetes from the SURDIAGENE (Survie, Diabete de type 2 et Genetique) study (discovery cohort) and the DIABHYCAR (Non-Insulin-Dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril) study (replication cohort). Global patterns of estimated glomerular filtration rate (eGFR) (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) and serum creatinine (SCr) prior to a major CV event (MACE) or last update were determined using a linear mixed-effects model and annual individual slopes computed by simple linear regression.
RESULTS: In the 1,040 participants of the discovery cohort, establishment of global patterns including 22,227 SCr over 6.3 years of follow-up showed an annual eGFR decline and an annual SCr increase that were significantly greater in patients with MACE compared with patients without (-3.0 and -1.7 mL/min/1.73 m(2)/year and +10.7 and +4.0 μmol/L/year, respectively; P < 0.0001 for both). Median annual individual slopes were also significantly steeper in patients with MACE, and adjusted risk of MACE was 4.11 times higher (3.09-5.45) in patients with rapid decline in eGFR (change less than -5 mL/min/1.73 m(2)/year). Consideration of renal function trajectories provided significant additive information helping to explain the occurrence of MACE for both SCr and eGFR (PIDI < 0.0001 and P = 0.0005, respectively). These results were confirmed in the replication cohort.
CONCLUSIONS: Renal function decline was associated with a higher risk of MACE. The pattern of renal function decline, beyond baseline kidney function, is an independent factor of CV risk.
© 2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27222502     DOI: 10.2337/dc15-2607

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  7 in total

1.  We Know More Than We Can Tell About Diabetes and Vascular Disease: The 2016 Edwin Bierman Award Lecture.

Authors:  Clay F Semenkovich
Journal:  Diabetes       Date:  2017-07       Impact factor: 9.461

2.  Temporal validation of the CT-PIRP prognostic model for mortality and renal replacement therapy initiation in chronic kidney disease patients.

Authors:  Dino Gibertoni; Paola Rucci; Marcora Mandreoli; Mattia Corradini; Davide Martelli; Giorgia Russo; Elena Mancini; Antonio Santoro
Journal:  BMC Nephrol       Date:  2019-05-17       Impact factor: 2.388

3.  The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study.

Authors:  Megumi Oshima; Min Jun; Toshiaki Ohkuma; Tadashi Toyama; Takashi Wada; Mark E Cooper; Samy Hadjadj; Pavel Hamet; Stephen Harrap; Giuseppe Mancia; Michel Marre; Bryan Williams; John Chalmers; Mark Woodward; Vlado Perkovic
Journal:  Diabetologia       Date:  2019-07-13       Impact factor: 10.122

4.  Modifiable factors related to 7-year renal outcomes in subjects with type 2 diabetes and chronic kidney disease stage 3.

Authors:  C H Huang; C P Chen; Y Y Huang; B R S Hsu
Journal:  J Postgrad Med       Date:  2020 Oct-Dec       Impact factor: 1.476

5.  Association of leukocyte telomere length with chronic kidney disease in East Asians with type 2 diabetes: a Mendelian randomization study.

Authors:  Resham L Gurung; Rajkumar Dorajoo; Yiamunaa M; Ling Wang; Sylvia Liu; Jian-Jun Liu; Yi Ming Shao; Yuqing Chen; Xueling Sim; Keven Ang; Tavintharan Subramaniam; Wern Ee Tang; Chee Fang Sum; Jian-Jun Liu; Su Chi Lim
Journal:  Clin Kidney J       Date:  2021-03-26

6.  Clinical and Pathological Features of Chinese Patients with Type 2 Diabetes, Biopsy-Proven Diabetic Kidney Disease, and Rapid eGFR Decline.

Authors:  Chunmei Qin; Yiting Wang; Lijun Zhao; Junlin Zhang; Honghong Ren; Yutong Zou; Yucheng Wu; Tingli Wang; Yuancheng Zhao; Rui Zhang; Huan Xu; Jie Zhang; Mark E Cooper; Fang Liu
Journal:  Diabetes Metab Syndr Obes       Date:  2022-09-16       Impact factor: 3.249

7.  Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?

Authors:  Shih-Chieh Shao; Yi-Han Lin; Kai-Cheng Chang; Yuk-Ying Chan; Ming-Jui Hung; Yea-Huei Kao Yang; Edward Chia-Cheng Lai
Journal:  BMJ Open Diabetes Res Care       Date:  2019-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.